Amlexanox
weak data
The Dose Guy’s verdictSep 1, 20262 sources
An old mouth-ulcer drug with a metabolic moonlight that looked exciting in mice and disappointing in people. The one human metabolic trial found a significant A1c reduction across the group, but only a subset improved on insulin sensitivity and liver fat, and that subset had a distinct baseline inflammatory signature that nobody can screen for outside a lab. The mechanism, targeting IKK-epsilon and TBK1 in the energy-wasting pathway, is genuinely novel. The payoff, for weight loss and metabolic improvement in the real world, is not there yet.
What it is
Amlexanox started as a topical anti-inflammatory for canker sores, FDA-approved in the 1990s as a 5% oral paste. Then researchers found it inhibits IKK-epsilon and TBK1, two kinases that obesity turns up in fat tissue, and that blocking them in obese mice restored energy expenditure, reversed insulin resistance, and cleared liver fat. That is an unusual pathway, completely separate from the appetite circuits the GLP-1 drugs work through, and it drew real attention.
The problem is translation. The mouse results were striking, the human pilot was not. Amlexanox is an approved drug with a known safety profile, which made it easy to test in people quickly, but “safe to try” and “effective” are different questions. On this shelf it sits as an interesting mechanism story without a convincing clinical payoff, the kind of compound researchers watch and vendors sell too early.
What the research shows
Mouse mechanism, clean. Human metabolic data, mixed:
Realistic protocols
The metabolic trial is the only human test of oral amlexanox for a metabolic indication. Some people try 25 mg three times daily to start and step up if tolerated, but there is no dose-response data to support the lower start beyond general caution.
The honest framing: you are running a drug whose metabolic effect showed up in a subset of one small trial, and you have no way to know if you are in that subset without baseline gene-expression profiling that no clinic offers. The expected payoff, even if you respond, is a modest glycemic improvement, not visible weight loss. If your primary goal is fat loss, this is the wrong compound, and retatrutide or tirzepatide are the right ones. If you are drawn to the mechanism and want to experiment, the safety profile from years of topical use and the small trial is at least reassuring for short runs.
Side effects
Well characterized from years of topical use and a small metabolic trial:
